It is important to note that DM associated with the anti-TIF1-γ antibody, present in 20% of adult cases, is particularly linked to malignancies.[10] In cases with positive anti-TIF1-γ, 60% to 90% of patients also have cancer.[11–13] Additionally, these patients may present with dysphagia, myositis, or elevated ferritin levels.[14] In such cases, comprehensive cancer screening is critical even if no malignancy is detected at the onset of DM.[15] Close monitoring for at least 3 years is recommended to identify any developing tumors.[14]. This evidence concerns the gene TRIM24 and dermatomyositis.